This text provides a brief insight into a report by AgencyIQ analyzing the drug approvals made by the FDA’s Center for Drug Evaluation and Research (CDER) in the first half of 2024. During this period, CDER approved 21 novel drug products. The analysis focuses on the number of these approvals that were based on a single pivotal trial. Additionally, it highlights an issue regarding the racial or ethnic diversity within some of these trials. Further details on this subject are available through a full article which can be accessed by filling out a form as indicated.
Note: To provide a more detailed summary, additional information beyond the short text provided would be required.
#Halfway #drug #approvals #supportive #clinical #trials #Exclusive #Analysis #Life #Science
